J
Jintao Zhang
Researcher at University of Kansas
Publications - 10
Citations - 243
Jintao Zhang is an academic researcher from University of Kansas. The author has contributed to research in topics: Druggability & DrugBank. The author has an hindex of 5, co-authored 10 publications receiving 228 citations.
Papers
More filters
Proceedings ArticleDOI
Inductive multi-task learning with multiple view data
Jintao Zhang,Jun Huan +1 more
TL;DR: In this paper, a new direction of multi-view learning where there are multiple related tasks with multi- view data is studied, or MVMT Learning, which learns a linear mapping for each view in each task.
Journal ArticleDOI
An efficient graph-mining method for complicated and noisy data with real-world applications
Yi Jia,Jintao Zhang,Jun Huan +2 more
TL;DR: A novel graph database-mining method called APGM (APproximate Graph Mining) to mine useful patterns from noisy graph database using a general framework for modeling noisy distribution using a probability matrix and an efficient algorithm to identify approximate matched frequent subgraphs.
Journal ArticleDOI
Towards comprehensive structural motif mining for better fold annotation in the "twilight zone" of sequence dissimilarity.
TL;DR: A theoretic framework is presented, a practical software implementation for incorporating prior domain knowledge, such as substitution matrices as studied here, and an efficient algorithm to identify approximate matched frequent subgraphs is devised.
Journal ArticleDOI
The BioAssay network and its implications to future therapeutic discovery
TL;DR: A model to quantitatively prioritize this druggability of bioassay targets being new drug targets in the context of complex biological networks is proposed and literature evidence was found to confirm the prioritization of bioASSay targets at a roughly 70% accuracy.
Journal ArticleDOI
Characterizing the Diversity and Biological Relevance of the MLPCN Assay Manifold and Screening Set
TL;DR: The analyses suggest that while MLI target selection has not yet been fully optimized for biochemical diversity, it covers biologically interesting pathway space that complements established drug targets and has greater biogenic bias than comparable collections of commercially available compounds.